Bionomics and CTx hit cancer treatment milestone
20 May, 2013 by Dylan Bushell-EmblingBionomics (ASX:BNO) and CTx said a compound from their VEGFR3 inhibitor program was able to suppress cancer progression in an animal model of melanoma.
Federal Budget fallout
15 May, 2013The 2013 Federal Budget has come down with cuts and pardons spread across the board for science, research, industry and education.
Partnership in sleep-disordered breathing
15 May, 2013The University of Sydney and ResMed have created a new partnership that will support research into sleep disorders.
Patrys study confirms PAT-SM6 effect in myeloma
08 May, 2013 by Dylan Bushell-EmblingA scientific article details the cancer cell killing effect that Patrys’ (ASX:PAB) anticancer antibody PAT-SM6 has in multiple myeloma.
Controlling lung inflammation in asthmatics
07 May, 2013The biggest study of its type in the world is investigating a possible new treatment for asthma sufferers.
Philanthropy, advocacy and vision
07 May, 2013 by Susan WilliamsonFour public organisations have joined forces to take an international approach in health and medical research advocacy.
Screening for Alzheimer’s disease
02 May, 2013 by Susan WilliamsonThe development of a blood test for the early detection of Alzheimer’s disease takes a step forward.
Schubert steps onto Garvan board
01 May, 2013Dr John Schubert has been elected Chairman of the Board at the Garvan.
Australian-made malaria vaccine to enter human trials
30 April, 2013Australian researchers have developed the first malaria vaccine that can be tailored to combat the many variants of malaria that exist around the world. Human trials of the vaccine will begin next year.
Patrys cleared to escalate dose in myeloma trial
24 April, 2013 by Dylan Bushell-EmblingThe safety board monitoring Patrys’s (ASX:PAB) phase I/IIa trial of PAT-SM6 in multiple myeloma has cleared the company to move up to a higher dose.
Reigniting cell death
22 April, 2013Australian researchers have taken an important step towards designing a potential new anticancer agent.
Patrys cancer antibody binds to two targets
22 April, 2013 by Dylan Bushell-EmblingLab studies into Patrys’s (ASX:PAB) cancer treatment candidate PAT-SM6 show that the antibody can bind to two separate targets.
AbbVie’s rheumatology tool proves popular
18 April, 2013A new web-based educational tool is engaging rheumatologists.
Professional development in therapeutics
13 April, 2013The ARCS Congress is coming up in Sydney at the beginning of June.
Taking breast cancer research into the clinic
12 April, 2013A team of Melbourne researchers has received funding to take their work on a new class of anticancer drugs out of the lab and into the clinic.
